BioChain (Beijing) Technology Co., Ltd.

Founded in 1994 in Silicon Valley, California, USA, BioChain (Beijing) Technology Co., Ltd. is a high-tech enterprise located in the Beijing Economic-Technological Development Area, integrating the R&D, production, and sales of in vitro diagnostic products and biological reagents, as well as biomedical translation and clinical medical testing services. The company focuses on the market for early tumor diagnosis and prenatal and postnatal diagnosis, committed to reducing tumor incidence and birth defect rates through convenient, effective, and economical early diagnosis and intervention products. BioChain is jointly composed of BioChain Institute Inc. (USA), BioChain (Beijing) Technology Co., Ltd., Beijing Modern Gaoda Biotechnology Co., Ltd., and Beijing BioChain Medical Laboratory. BioChain brings together outstanding domestic and international talents, aiming to develop early tumor diagnosis products suitable for China's national conditions, and to make early tumor diagnosis products affordable for the people. BioChain has cooperated with the National Cancer Center (NCC) of China, the National Cancer Institute (NCI) of the USA, Cancer Hospital of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing Cancer Hospital, Beijing Military General Hospital, Xijing Hospital, Shanghai Changhai Hospital, Fudan University Shanghai Cancer Center, and other scientific and clinical units to jointly develop early tumor diagnosis products. BioChain is the first company in China to have a non-invasive early colorectal cancer gene methylation diagnostic kit, the first in China to have a 'high-throughput alpha- and beta-thalassemia gene detection kit', the first in China to obtain a 'TORCH comprehensive detection kit', the first in China to have a 'hepatitis full-series detection kit', and the first in China to have a 'tuberculosis colloidal gold immunochromatographic assay detection kit'. BioChain owns the first tumor gene methylation diagnostic product platform, an automated gene methylation sample processing platform (equipment and consumables), and a combined gene methylation and protein immunoassay detection platform. The company's independent R&D achievements have filled multiple gaps in the early detection of colorectal cancer, gastric cancer, lung cancer, and other tumors both domestically and internationally. We believe that defeating tumors depends on early diagnosis, and the purpose of early diagnosis is for more effective intervention. After more than 20 years of unremitting efforts, BioChain adheres to the goal of industrializing early tumor diagnosis products with independent intellectual property rights, focuses on the forefront of international biomedical research achievements, and bases on diagnostic application platforms suitable for national conditions. Step by step, it has built an internationally first-class research, development, and application platform for tumor and genetic disease molecular diagnostic products, and through collaborative innovation, has continuously transformed the latest diagnostic technology achievements at home and abroad into clinical diagnostic products and applications suitable for China's national conditions. In the fields of tumor molecular diagnostic reagents, automation of clinical sample processing, and molecular diagnostic equipment, BioChain owns dozens of domestic and international invention patents and exclusive patent licenses. BioChain has multiple diagnostic product production lines that meet GMP certification standards, mainly including: gene methylation diagnostic reagents, nucleic acid diagnostic reagents, multi-index diagnostic reagents, enzyme-linked immunoassay diagnostic reagents, POCT diagnostic reagents, and gene methylation automated processing equipment and reagents. The company's early tumor diagnosis products are characterized by high sensitivity, strong specificity, simple operation, safety and reliability, and economical pricing, and can gradually meet the needs of different customers such as tumor treatment effect monitoring, clinical follow-up examinations, high-risk population screening, and general population screening. Based on the clinical diagnostic market demand at home and abroad, BioChain introduces international cutting-edge technologies and applications, forming a systematic industrial chain from basic research accumulation, clinical diagnostic project translation, and industrialization of diagnostic products to third-party medical testing services. The 'BioChain International Cooperation Base for Clinical Diagnostics', built by BioChain in the core area of the Beijing Economic-Technological Development Area, consists of the translational R&D center, international exchange center, clinical medical testing center, production center, and comprehensive support center, with a total construction area of nearly 40,000 square meters. Early tumor diagnosis and intervention is a heavy responsibility that requires the joint efforts of all humanity and society. BioChain hopes that more forward-looking individuals will unite their strength for themselves, their families, and the nation, to achieve early diagnosis and early intervention, and defeat tumors.